RIPK1 and amyotrophic lateral sclerosis: Additionally, from the perspective of “drug repurposing,” a clinical trial was carried out, revealing that “Primidone” could reduce the levels of necroptosis biomarker RIPK1 and the inflammatory cytokine interleukin-8 (IL-8) in ALS patients (Wei et al., 2023).